Pharmbio Korea Co Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Pharmbio Korea Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10512
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Pharmbio Korea Co Ltd (Pharmbio) is a pharmaceutical company that manufactures and markets original prescribing drugs and OTC drugs for various therapeutic segments. The company offers products in therapeutic areas of urology, gastroenterology, pediatrics, pain control, obstetrics and gynaecology products, among others. Its products include urocitra, rowatinex, rowachol and hepadial. Pharmbio’s rowatinex promotes diuresis and relaxes urinary tract spasm for assisting the passage of stones. Its rowachol is indicated for the treatment of hepato-biliary disorders including the dissolution of gallstones. The company offers its products in the dosage forms of solutions, powders and tablets. It markets its products through its network of distributors. Pharmbio is headquartered in Seoul, South Korea.

Pharmbio Korea Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Pharmbio Korea Enters into Licensing Agreement with Trevena 10
Pharmbio Korea Enters into Licensing Agreement with Shionogi 11
Pharmbio Korea Enters into Licensing Agreement with Faron Pharma 12
Pharmbio Korea Co Ltd – Key Competitors 13
Pharmbio Korea Co Ltd – Key Employees 14
Pharmbio Korea Co Ltd – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Pharmbio Korea Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Pharmbio Korea Enters into Licensing Agreement with Trevena 10
Pharmbio Korea Enters into Licensing Agreement with Shionogi 11
Pharmbio Korea Enters into Licensing Agreement with Faron Pharma 12
Pharmbio Korea Co Ltd, Key Competitors 13
Pharmbio Korea Co Ltd, Key Employees 14

List of Figures
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Pharmbio Korea Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Pharmbio Korea Co Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kalle GmbH:企業の戦略的SWOT分析
    Kalle GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • DTE Energy Co (DTE):電力:M&Aディール及び事業提携情報
    Summary DTE Energy Company (DTE Energy) is a diversified energy company that develops and manages energy-related businesses and services. It has presence in the electricity value chain from generation, procurement, to transmission, distribution, and sales. The company procures, stores, and transport …
  • Event Hospitality & Entertainment Ltd:企業の戦略・SWOT・財務分析
    Event Hospitality & Entertainment Ltd - Strategy, SWOT and Corporate Finance Report Summary Event Hospitality & Entertainment Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • The Walsh Group Ltd:企業の戦略的SWOT分析
    The Walsh Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Zenkyoren:企業の戦略・SWOT・財務情報
    Zenkyoren - Strategy, SWOT and Corporate Finance Report Summary Zenkyoren - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • ProteoMediX AG-医療機器分野:企業M&A・提携分析
    Summary ProteoMediX AG (ProteoMediX) is a medical diagnostic company which identifies and develops novel biomarkers for the early detection of cancer and the personalized treatment. The company develops non-invasive diagnostic tests for the detection, prognosis, stratification, and therapy-selection …
  • Bio-Reference Laboratories Inc:企業の戦略的SWOT分析
    Bio-Reference Laboratories Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Wakefern Food Corp.:企業の戦略的SWOT分析
    Wakefern Food Corp. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Rex Energy Corp (REXX):石油・ガス:M&Aディール及び事業提携情報
    Summary Rex Energy Corp (Rex Energy) is an independent energy company. It carries out the acquisition, production, exploration and development of condensate, natural gas and natural gas liquids. It holds properties in Appalachian Basin. Rex Energy focuses on drilling and exploration activities in th …
  • Supreme Group B.V.
    Supreme Group B.V. - Strategy, SWOT and Corporate Finance Report Summary Supreme Group B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Emmi AG:企業のM&A・事業提携・投資動向
    Emmi AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Emmi AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …
  • Kansai Paint Co Ltd (4613):企業の財務・戦略的SWOT分析
    Kansai Paint Co Ltd (4613) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Washington University School of Medicine-製薬・医療分野:企業M&A・提携分析
    Summary Washington University School of Medicine (WUSTL), a subsidiary of University of Washington is a medical university that offers patient care, research, education services and neurology clinical trials. The university provides patient care services such as clinical, find a doctor, referring ph …
  • Edgemont Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析
    Summary Edgemont Pharmaceuticals LLC (Edgemont) is a pharmaceutical company that develops, acquires, and markets products for the treatment of psychiatric disorders. The company focuses on the development of novel drug formulations and therapies in the field of neuroscience. Its portfolio of product …
  • AMAG Pharmaceuticals Inc (AMAG):医療機器:M&Aディール及び事業提携情報
    Summary AMAG Pharmaceuticals Inc (AMAG) develops and commercializes specialty pharmaceutical products with focus on maternal health, anemia management and cancer supportive care. It develops and markets products used to reduce the risk of preterm birth in women with a single baby who have a history …
  • Vancouver City Savings Credit Union:企業の戦略・SWOT・財務情報
    Vancouver City Savings Credit Union - Strategy, SWOT and Corporate Finance Report Summary Vancouver City Savings Credit Union - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Sentien Biotechnologies Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Sentien Biotechnologies Inc (Sentien) is a clinical stage biotechnology company that develops novel delivery approaches to cell therapy. The company’s lead product SBI-101 is used for the treatment of patients with severe acute kidney injury (AKI). Its Sentinel is designed to enable controll …
  • lululemon athletica inc.:企業の戦略・SWOT・財務情報
    lululemon athletica inc. - Strategy, SWOT and Corporate Finance Report Summary lululemon athletica inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Zenotech Laboratories Ltd (532039):企業の財務・戦略的SWOT分析
    Zenotech Laboratories Ltd (532039) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Cytune Pharma SAS-製薬・医療分野:企業M&A・提携分析
    Summary Cytune Pharma SAS (Cytune) is a developer of immunotherapeutic agents for the treatment of cancer and infectious diseases. The company’s product portfolio includes recombinant proteins and monoclonal antibodies. Its CYP0150 is a recombinant protein, which decreases metastasis numbers, tumor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆